Your Messages Inbox
Your Article Summary
See Latest ArticlesFDA Approves KAPIDEX (dexlansoprazole) delayed release capsules for the Treatment of GERD
Takeda Pharmaceuticals North America, 02/02/09
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., announced that the U.S. Food and Drug Administration (FDA) approved KAPIDEX (dexlansoprazole) delayed release capsules for the once-daily, oral treatment of heartburn associated with symptomatic non-erosive Gastroesophageal Reflux Disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE. KAPIDEX (30 mg and 60 mg) is the first proton pump inhibitor (PPI) with a Dual Delayed Release (DDR) formulation designed to provide two separate releases of medication.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
Gilead, 11/25/09
Boston Scientific Announces FDA Clearance and CE Mark for WallFlex Fully Covered Esophageal Stent
Boston Scientific, 11/24/09
AstraZeneca submits US New Drug Application for ticagrelor, an investigational antiplatelet agent
AstraZeneca, 11/23/09
Article Search
Sponsor